UniProt/SwissProt ID: | ANXA1_HUMAN |
Description: | annexin A1 [Source:HGNC Symbol;Acc:533] |
Location: | chr9 q21.13 |
Node attribute: | ligand; substrate |
Phosphorylation site |
Position | PhosphoPeptide | Catalytic kinase | Source |
---|---|---|---|
T88 | AYLQEtGKPLD | Annexin | PhosphoSitePlus |
Y21 | NEEQEyVQTVK | EGFR | phosphoELM; RegPhos; SysPTM |
S28 | QTVKSsKGGPG | PhosphoSitePlus | |
T41 | VSPYPtFNPSS | PhosphoSitePlus | |
S5 | FLKQ | TRPM7 | HPRD |
S45 | PTFNPsSDVAA | PhosphoSitePlus | |
S34 | KGGPGsAVSPY | PhosphoSitePlus | |
T70 | IIDILtKRNNA | Annexin | PhosphoSitePlus |
Y39 | SAVSPyPTFNP | PhosphoSitePlus; HPRD; phosphoELM | |
S5 | MAMVSeFLKQ | ChaK1(TRPM7 | RegPhos |
Y207 | DARALyEAGER | Annexin | PhosphoSitePlus |
T24 | QEYVQtVKSSK | PKC_group | phosphoELM; RegPhos |
S27 | VQTVKsSKGGP | PKCa(PKC alpha | RegPhos |
T169 | LAKDItSDTSG | Annexin | PhosphoSitePlus |
S27 | VQTVKsSKGGP | PhosphoSitePlus | |
T24 | QEYVQtVKSSK | RegPhos | |
S28 | QTVKSsKGGPG | PKC_group | phosphoELM; RegPhos |
T226 | FNTILtTRSYP | Annexin | PhosphoSitePlus |
Y21 | NEEQEyVQTVK | PhosphoSitePlus; SysPTM | |
T216 | ERRKGtDVNVF | HPRD; RegPhos | |
S27 | VQTVKsSKGGP | PKCi | RegPhos |
Y21 | NEEQEyVQTVK | Src | RegPhos; SysPTM |
S37 | PGSAVsPYPTF | PhosphoSitePlus; HPRD | |
S170 | AKDITsDTSGD | HPRD; SysPTM | |
T172 | DITSDtSGDFR | Annexin | PhosphoSitePlus |
T216 | ERRKGtDVNVF | PKA_group | phosphoELM; RegPhos |
Y21 | NEEQEyVQTVK | Abl | phosphoELM; SysPTM |
Y21 | NEEQEyVQTVK | SRC | HPRD; phosphoELM; RegPhos; SysPTM |
S5 | MAMVSeFLKQ | ChaK1 | RegPhos |
S5 | MAMVSeFLKQ | RegPhos | |
S27 | VQTVKsSKGGP | PKC_group | phosphoELM; RegPhos |
S27 | VQTVKsSKGGP | PRKCI | HPRD |
S5 | _MAMVsEFLKQ | PhosphoSitePlus | |
S27 | VQTVKsSKGGP | PKC_alpha | phosphoELM |
Y240 | RVFQKyTKYSK | Annexin | PhosphoSitePlus |
T216 | ERRKGtDVNVF | Annexin | PhosphoSitePlus |
Y335 | ETKGDyEKILV | Annexin | PhosphoSitePlus |
Y21 | NEEQEyVQTVK | ABL1 | RegPhos; SysPTM |
S5 | FLKQ | phosphoELM | |
S170 | AKDITsDTSGD | Annexin | PhosphoSitePlus; SysPTM |
T64 | GVDEAtIIDIL | Annexin | PhosphoSitePlus |
Y207 | DARALyEAGER | HPRD; phosphoELM; RegPhos | |
Y84 | QIKAAyLQETG | Annexin | PhosphoSitePlus |
Y230 | LTTRSyPQLRR | Annexin | PhosphoSitePlus |
S173 | ITSDTsGDFRN | Annexin | PhosphoSitePlus |
Dephosphorylation site |
ANXA1_HUMAN do not have dephosphorylation site. |
Mutation site |
Ensembl ID | Variation | Source | Cancer name | Pubmed |
---|---|---|---|---|
ENSP00000366109 | *347C | COSMIC | Ovarian Cancer | 21720365 |
ENSP00000257497 | G333E | TCGA | Neoplasms by Histologic Type | 21720365, 18772890 |
ENSP00000366109 | G333E | TCGA | Neoplasms by Histologic Type | 21720365, 18772890 |
ENSP00000257497 | G333E | COSMIC | Central Nervous System Neoplasms | 18772890 |
ENSP00000366109 | *347S | COSMIC | Ovarian Cancer | 21720365 |
ENSP00000257497 | *347C | COSMIC | Ovarian Cancer | 21720365 |
ENSP00000366109 | G333E | COSMIC | Central Nervous System Neoplasms | 18772890 |
ENSP00000257497 | *347S | COSMIC | Ovarian Cancer | 21720365 |
Differential expressed protein |
Ensembl ID | Cancer name | Design | Sample | Change | Ratio | Pubmed |
---|---|---|---|---|---|---|
ENSP00000366109 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 17537172 | |
ENSP00000366109 | Gastric Cancer | Metastasis | cell line | Down | 0.68 | 17022644 |
ENSP00000366109 | Prostate Cancer | Metastasis | cell line | Up | 8.3 | 15102926 |
ENSP00000366109 | Uterine Cancer | Normal vs. Cancer | tissue | Down | 17902640 | |
ENSP00000366109 | colorectal cancer | Metastasis | cell line | Down | 17503081 | |
ENSP00000366109 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 3.9 | 16788983 |
ENSP00000366109 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 5 | 16788983 |
ENSP00000366109 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 13 | 18665625 |
ENSP00000366109 | papillary thyroid carcinoma | Normal vs. Cancer | tissue | Up | 5.7 | 18665625 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.24 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.25 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.28 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.32 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.33 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.36 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.4 | 19142970 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.41 | 19142970 |
ENSP00000366109 | Breast Cancer | Treatment (metastasis vs. metastasis-suppressed BRMS1) | cell line | Down | 15168732 | |
ENSP00000366109 | Breast Cancer | Treatment (chemosensitive vs. adriamycin-resistant) | cell line | Up | 17487377 | |
ENSP00000366109 | Neoplasms by Histologic Type | Normal vs. Cancer | tissue | Up | 3.1 | 18259946 |
ENSP00000366109 | Neoplasms by Histologic Type | Normal vs. Cancer | tissue | Up | 1.9 | 18259946 |
ENSP00000366109 | Hepatocellular Carcinoma | Cancer vs. Cancer (HCC vs. HuCCA) | cell line | Up | 20069059 | |
ENSP00000366109 | Lung Cancer | Cancer vs. Cancer | cell line | Up | 17284061 | |
ENSP00000366109 | Non-small cell lung carcinoma | Metastasis | cell line | Down | 0.28 | 17418446 |
ENSP00000366109 | Lung Cancer | Treatment(none vs 20 mg/mL GTE treatment) | cell line | Up | 3 | 19137550 |
ENSP00000366109 | Lung Cancer | Treatment(none vs 40 mg/mL GTE treatment) | cell line | Up | 3.3 | 19137550 |
ENSP00000366109 | Lung Cancer | Treatment (none vs transfected with pc3.1-hPNAS5) | cell line | Up | 19795389 | |
ENSP00000366109 | Gastric Cancer | Metastasis | cell line | Down | 0.68 | 17022644 |
ENSP00000366109 | Gastric Cancer | Treatment (none vs. Vincristine-resistant) | cell line | Up | 2.4 | 18253933 |
ENSP00000366109 | Gastric Cancer | Cancer vs. Cancer (good vs. proo survival) | tissue | Down | 0.38 | 18830628 |
ENSP00000366109 | Gastric Cancer | Normal vs. Cancer | tissue | Up | 7 | 19330469 |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.25 | 20052998 |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | cell line | Down | 0.97 | 20052998 |
ENSP00000366109 | Breast Cancer | Metastasis | cell line | Up | 4 | 20052998 |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | tissue | Up | 1.8 | 20087651 |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | cell line | Up | 1.5 | 20543960 |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | tissue | Down | 20560667 | |
ENSP00000366109 | Breast Cancer | Cancer vs. Cancer (Non-TNBC vs. TNBC) | cell line | Up | 20596302 | |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | tissue | Down | 0.74 | 20739354 |
ENSP00000366109 | Breast Cancer | Normal vs. Cancer | tissue | Down | 0.74 | 20739354 |
ENSP00000366109 | breast ductal carcinoma | Normal vs. Cancer | tissue | Up | 18564057 | |
ENSP00000366109 | Oral Cancer | Normal vs. Cancer | tissue | Down | 0.2 | 19691830 |
ENSP00000366109 | chronic myeloid leukemia | Treatment (Imatinib-sensitive vs. Imatinib-resistant) | cell line | Down | 20417730 | |
ENSP00000366109 | Leukemia | Cancer vs. Cancer (subtype) | tissue | Up | 15501966 | |
ENSP00000366109 | Renal Cancer | Normal vs. Cancer | tissue | Up | 1.1-5.7 | 12923786 |
ENSP00000366109 | Neoplasms by Histologic Type | Cancer vs. Cancer (subtype) | tissue | Up | 1.4 | 16807943 |
ENSP00000366109 | Ovarian Cancer | Metastasis | cell line | Up | 3 | 17892554 |
ENSP00000366109 | Ovarian Cancer | Metastasis | cell line | Down | 17892554 | |
ENSP00000366109 | Pancreatic Cancer | Normal vs. Cancer | tissue | Up | 4 | 15526344 |
ENSP00000366109 | Esophageal Cancer | Normal vs. Cancer | tissue | Down | 0.5 | 16400690 |
ENSP00000366109 | Uterine Cancer | Normal vs. Cancer | tissue | Down | 16051329 | |
ENSP00000366109 | Uterine Cancer | Normal vs. Cancer | tissue | Down | 19771267 | |
Hyperphosphorylation site |
ANXA1_HUMAN do not have hyperphosphorylation site. |
Direct Interaction Pair |
Source | Target | Relationship | Resource |
---|---|---|---|
ANXA1_HUMAN | FPR1_HUMAN | ligand -> receptor | HPMR |
TRPM7_HUMAN | ANXA1_HUMAN | kinase -> substrate | HPRD |
ZAGL2_HUMAN | ANXA1_HUMAN | kinase -> substrate | RegPhos |
ABL1_HUMAN | ANXA1_HUMAN | kinase -> substrate | RegPhos |
FGR_HUMAN | ANXA1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
KPCI_HUMAN | ANXA1_HUMAN | kinase -> substrate | HPRD |
SRC_HUMAN | ANXA1_HUMAN | kinase -> substrate | HPRD; RegPhos |
EGFR_HUMAN | ANXA1_HUMAN | kinase -> substrate | RegPhos |
KPCA_HUMAN | ANXA1_HUMAN | kinase -> substrate | Robert H Newman (2013) |
Function Annotation |
KEGG Pathway |
ANXA1_HUMAN is not in KEGG pathway. |
Gene Ontology |
GO ID | GO_Term | Evidence | Ontology |
---|---|---|---|
GO:0005615 | extracellular space | IEA | cellular_component |
GO:0005544 | calcium-dependent phospholipid binding | IEA | molecular_function |
GO:0042803 | protein homodimerization activity | IEA | molecular_function |
GO:0005102 | receptor binding | TAS | molecular_function |
GO:0007165 | signal transduction | TAS | biological_process |
GO:0042383 | sarcolemma | IEA | cellular_component |
GO:0014070 | response to organic cyclic compound | IEA | biological_process |
GO:0006954 | inflammatory response | TAS | biological_process |
GO:0043065 | positive regulation of apoptotic process | IEA | biological_process |
GO:0018149 | peptide cross-linking | IDA | biological_process |
GO:0005886 | plasma membrane | IEA | cellular_component |
GO:0031966 | mitochondrial membrane | IEA | cellular_component |
GO:0007049 | cell cycle | IEA | biological_process |
GO:0031018 | endocrine pancreas development | IEA | biological_process |
GO:0005509 | calcium ion binding | IEA | molecular_function |
GO:0005543 | phospholipid binding | TAS | molecular_function |
GO:0051384 | response to glucocorticoid stimulus | IEA | biological_process |
GO:0005515 | protein binding | IPI | molecular_function |
GO:0097350 | neutrophil clearance | IMP | biological_process |
GO:0043066 | negative regulation of apoptotic process | IEA | biological_process |
GO:0001780 | neutrophil homeostasis | IEA | biological_process |
GO:0031340 | positive regulation of vesicle fusion | IDA | biological_process |
GO:0007165 | signal transduction | IEA | biological_process |
GO:0050482 | arachidonic acid secretion | IEA | biological_process |
GO:0005198 | structural molecule activity | IDA | molecular_function |
GO:0005737 | cytoplasm | IEA | cellular_component |
GO:0030073 | insulin secretion | IEA | biological_process |
GO:0016323 | basolateral plasma membrane | IEA | cellular_component |
GO:0006928 | cellular component movement | TAS | biological_process |
GO:0005576 | extracellular region | TAS | cellular_component |
GO:0005929 | cilium | IEA | cellular_component |
GO:0030674 | protein binding, bridging | IDA | molecular_function |
GO:0070365 | hepatocyte differentiation | IEA | biological_process |
GO:0030216 | keratinocyte differentiation | IDA | biological_process |
GO:0070301 | cellular response to hydrogen peroxide | IEA | biological_process |
GO:0046632 | alpha-beta T cell differentiation | IEA | biological_process |
GO:0060206 | estrous cycle phase | IEA | biological_process |
GO:0005634 | nucleus | IEA | cellular_component |
GO:0043434 | response to peptide hormone stimulus | IEA | biological_process |
GO:0001533 | cornified envelope | IDA | cellular_component |
GO:0071385 | cellular response to glucocorticoid stimulus | IEA | biological_process |
GO:0050709 | negative regulation of protein secretion | IEA | biological_process |
GO:0005515 | protein binding | IEA | molecular_function |
GO:0007166 | cell surface receptor signaling pathway | IEA | biological_process |
GO:0002674 | negative regulation of acute inflammatory response | IEA | biological_process |
GO:0005543 | phospholipid binding | IEA | molecular_function |
GO:0042493 | response to drug | IEA | biological_process |
GO:0032355 | response to estradiol stimulus | IEA | biological_process |
GO:0010165 | response to X-ray | IEA | biological_process |
GO:0043234 | protein complex | IEA | cellular_component |
GO:0005737 | cytoplasm | IDA | cellular_component |
GO:0031394 | positive regulation of prostaglandin biosynthetic | IEA | biological_process |
GO:0009725 | response to hormone stimulus | IEA | biological_process |
GO:0070555 | response to interleukin-1 | IEA | biological_process |
GO:0042063 | gliogenesis | IEA | biological_process |
GO:0042127 | regulation of cell proliferation | IEA | biological_process |
GO:0031960 | response to corticosteroid stimulus | IEA | biological_process |
GO:0005886 | plasma membrane | IDA | cellular_component |
GO:0019834 | phospholipase A2 inhibitor activity | IEA | molecular_function |
GO:0070062 | extracellular vesicular exosome | IDA | cellular_component |
GO:0033031 | positive regulation of neutrophil apoptotic proces | IEA | biological_process |